Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-16-019116
Filing Date
2016-05-11
Accepted
2016-05-11 16:47:13
Documents
54
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q abio-10q_20160331.htm 10-Q 1360889
2 EX-31.1 abio-ex311_9.htm EX-31.1 8620
3 EX-31.2 abio-ex312_7.htm EX-31.2 8569
4 EX-32.1 abio-ex321_8.htm EX-32.1 11459
  Complete submission text file 0001564590-16-019116.txt   4645690

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT abio-20160331.xml EX-101.INS 957997
6 XBRL TAXONOMY EXTENSION SCHEMA abio-20160331.xsd EX-101.SCH 36458
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE abio-20160331_cal.xml EX-101.CAL 33500
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE abio-20160331_def.xml EX-101.DEF 95492
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE abio-20160331_lab.xml EX-101.LAB 292658
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE abio-20160331_pre.xml EX-101.PRE 212425
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-22873 | Film No.: 161640475
SIC: 2835 In Vitro & In Vivo Diagnostic Substances